Merck management commentary: New products drive 5% revenue growth in Q3 2026

By Public Technologies
  • Merck's management commentary attributed third-quarter 2026 revenue growth of 5% to $18.1 billion to new products, oncology and animal health.
  • Keytruda-family sales rose 6% excluding currency effects to $8.6 billion, driven by earlier-stage cancer uptake and metastatic demand.
  • Non-GAAP operating expenses increased 12% to $7.4 billion, reflecting launch investments, pipeline spending and a licensing charge.
  • Full-year revenue guidance narrowed to $66.8 billion–$67.3 billion; non-GAAP EPS guidance narrowed to $2.77–$2.82, with both midpoints raised.
  • Favorable U.S. purchase timing boosted quarterly sales by approximately $550 million; Keytruda and Winrevair benefits are expected to reverse in the fourth quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.